NLRP3 and pulmonary arterial hypertension: We used the NLRP‐3 inflammasome inhibitor (MCC950) and the calpain‐1 inhibitor (MDL‐28170) to verify that AS‐IV protected rats against pulmonary hypertension induced by MCT through the NLRP‐3/calpain‐1 signalling pathway.